Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have been assigned a consensus recommendation of “Moderate ...
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its price objective lifted by analysts at Morgan Stanley from $16.00 ...
Hosted on MSN20d
Nurix Therapeutics appoints new chief commercial officerSAN FRANCISCO - Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in targeted protein modulation drugs, announced today the appointment of John Northcott as its new ...
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in ...
Nurix Therapeutics (NRIX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...
DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...
Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib SAN FRANCISCO, ...
About Nurix Therapeutics, Inc. Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback